Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.
相关临床试验
1
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
1
100.0%
暂无批准数据
- Thermo Fisher Scientific has completed its $8.875 billion acquisition of Clario Holdings, a leading provider of endpoint data solutions for clinical trials, following EU regulatory approval. - Clario's platform has supported approximately 70% of FDA and EMA novel drug approvals over the past decade through its imaging, eCOA, and precision motion technologies. - The acquisition is expected to contribute $0.45 of adjusted earnings per share in the first year and generate approximately $175 million in synergies by year 5. - The combined entity targets high single-digit growth with the deal providing a double-digit internal rate of return for Thermo Fisher.
• The U.S. healthcare contract research organization market is expected to grow from $15.01 billion in 2025 to $29.68 billion by 2034, driven by increasing R&D investments and technological advancements. • Artificial intelligence integration is revolutionizing CRO operations through enhanced clinical trial design, automated data management, and improved patient recruitment, significantly boosting efficiency and productivity. • The preclinical CRO segment is projected to reach $4.66 billion by 2034, with an 8.2% CAGR, as pharmaceutical companies increasingly outsource specialized research services to reduce costs and accelerate drug development.
• The global clinical trial outsourcing market is projected to grow from $43.1 billion in 2025 to $91.2 billion by 2034, representing a robust CAGR of 7.46% as pharmaceutical companies increasingly rely on CROs to streamline research processes. • Advanced technologies including AI, machine learning, and blockchain are transforming clinical trial management, enhancing efficiency and accelerating drug approvals while creating new opportunities for market participants. • North America dominates the market due to its strong pharmaceutical industry and favorable regulatory environment, while Asia-Pacific is emerging as a high-growth region offering cost advantages and large patient populations.
